All In MedTech

Device Trial Radar · NCT07792252

REWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness

A Prospective Observational Real-World Evidence Study of a 510(k)-Cleared Prescription Digital Therapeutic in Patients Receiving Interventional Treatment for Major Depressive Disorder

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Yale UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Otsuka Pharmaceutical Co., Ltd.
First posted
Aug 28, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rejoyn is a Prescription Digital Therapeutic (PDT) for adults with Major Depressive Disorder (MDD). This study aims to evaluate the feasibility, engagement, and clinical context of integrating Rejoyn into standard interventional workflows at the Yale New Haven Hospital Interventional Psychiatry Service (IPS). This is a non-significant risk, observational real-world evidence (RWE) study.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

  • RejoynDevice

    Rejoyn is a 510(k)-cleared Prescription Digital Therapeutic (PDT) for adults with Major Depressive Disorder (MDD) as an adjunct to clinician-managed treatment.

  • Cognitive Behavioral Therapy (CBT) exercisesBehavioral

    Cognitive Behavioral Therapy (CBT) exercises, followed by an additional 6 weeks of access to the CBT content for additional review.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients prescribed RejoynTime frame: From screening through enrollment, approximately 1 week
  2. Mean participant app use to assess engagementTime frame: up to Week 12
  3. Mean duration of app use to assess engagementTime frame: up to Week 12

2 more outcomes with a free account

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Yale Greenwich Hospital Interventional Psychiatry Services

    Greenwich, Connecticut

  • Yale New Haven Hospital Interventional Psychiatry Services

    New Haven, Connecticut

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.